
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana is currently in a strong position with its niche focus on government-sponsored healthcare programs, as well as its wide range of healthcare services. They have shown strong performance in terms of medical membership and closely monitor their financials to maintain their targeted margins. With upcoming catalysts such as the launch of plan finder and release of Star Ratings, the company is well-positioned for future growth.
Bears say
Humana is highly reliant on government-sponsored programs for nearly all of its medical membership, with limited exposure to commercial insurance. The company faces margin pressure from rising medical costs and potential benefit cuts, which could hinder its ability to regain normalized margins in the next decade. The uncertainty surrounding industry thresholds and potential adjustments in the Medicare Advantage program also add to the complexity and risk of investing in this stock. Additionally, Humana's current valuation of 15.5x 2027E EPS may be too optimistic, considering the company's challenges and potential impacts on its core operating performance.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares